Gaps in Global Antiviral Research and Development
Global antiviral R&D is slowing when the world can least afford it, new analysis shows.
The INTREPID Alliance has released its fourth edition of the Antiviral Clinical and Preclinical Development Landscape, offering a detailed view of small-molecule antiviral compounds in the global pipeline. Alarmingly, the report indicates a halt in the momentum of antiviral research and development at a time when addressing pandemic preparedness is critical. The analysis synthesizes data from over 200 programs targeting 13 viral families, exposing areas where progress is evident and where critical gaps are apparent.
Current analysis emphasizes that the surge of clinical and preclinical antiviral investigations is primarily focused on viruses linked to COVID-19 and influenza. Conversely, there is inadequate exploration and development of treatments for Mpox, Dengue, Ebola, and Lassa fever. Concerningly, some viral families that pose pandemic threats currently lack any compounds in development, increasing the risk of future outbreaks.
Concerns Over Current Antiviral Development Trends
James Anderson, the Executive Director of Global Health at the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Chair of the INTREPID Alliance Board, has voiced grave concerns regarding the current trajectory of antiviral research. He stated, "We are going backwards, not forwards. Despite the lessons learned from the COVID-19 pandemic, there is a decline in the investment directed toward small-molecule antivirals at a crucial time. Our world remains perilously vulnerable to emerging viral threats—and without a strong antiviral pipeline, we are at risk." He describes the report as "both a wake-up call and a roadmap for more efficient preparedness."
Key Findings from the Report
The fourth edition landscape report outlines significant findings crucial for understanding the state of antiviral development:
- Clinical pipeline: Currently, there are 67 distinct antiviral compounds in active clinical development. Among these, 22 have received approval, with 42 being novel candidates that are not yet approved. However, the overall count of new clinical candidates has plateaued since the last report, indicating stagnation in advancement.
- Preclinical pipeline: 168 novel compounds are currently in preclinical stages focused on 189 virus-disease indications. Yet, the majority of these compounds still aim at tackling SARS-CoV-2, leaving many priority viral families insufficiently addressed.
- R&D concentration: Nearly 90% of clinical developments are predominately spearheaded by biopharmaceutical companies, while early-stage research showcases a broader participation from academia and government entities. Nonetheless, development remains largely concentrated within high-income nations, pointing to a pressing need for enhanced global participation.
The Urgency of Antiviral Research
The recency of Mpox disease outbreaks has forced the World Health Organization to announce public health emergencies, underscoring how ill-prepared the world is for emerging diseases. In response, the INTREPID Alliance has called for increased investments in antiviral research for Mpox and other orthopoxviruses, emphasizing that it is not only a scientific matter but a significant global security concern. According to Kelly Chibale, Ph.D., Professor and Neville Isdell Chair in African-centric Drug Discovery and Development, "A strong antiviral pipeline is crucial in safeguarding global health in our interconnected world. We need innovation reaching the areas most vulnerable to future outbreaks."
Conclusion and Future Directions
INTREPID’s reports play a key role in supporting the 100 Days Mission, which aims to ensure that timely interventions can be made within the first hundred days after identifying a new pandemic threat. The research carried out by INTREPID seeks to aid policymakers and the global scientific community in identifying urgent needs and impactful opportunities within antiviral research and development.
To access comprehensive insights including methodology and interactive data on the antiviral clinical development pipeline, visit INTREPID's official platform. The INTREPID Alliance aims to bridge the gaps in antiviral solutions, ensuring swift progress towards effective treatments for pathogens with the potential to cause pandemics.
Frequently Asked Questions
What is the INTREPID Alliance?
The INTREPID Alliance is a non-profit consortium focused on accelerating the development of antiviral treatments for pandemic threats through research, advocacy, and stakeholder engagement.
What did the recent report reveal?
The report highlighted that global antiviral research is stalling, with many potential pandemic threats lacking adequate furthering in research and development.
What are the major findings from the report?
The key findings show a plateau in clinical candidates, a concentration of research in high-income countries, and underdevelopment of compounds targeting several key viral families.
Why is the antiviral pipeline crucial?
A strong antiviral pipeline is essential for global health security against emerging viral threats, ensuring rapid response capabilities during outbreaks.
How can the public engage with INTREPID's findings?
INTREPID encourages public engagement through their reports and findings, which are freely accessible and aimed at informing policy decisions in global health.
